AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9894821 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented group (multivitamin alone)
Number of subjects: 190
Study 7659483 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccine (WCL)
Number of subjects: 2127
Study 7659483 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis vaccine (DTaP)
Number of subjects: 2127
Study 2568805 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan 280 (0.15 to 0.9 g I/kg body weight)
Number of subjects: 12
Study 2568805 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan 280 (0.9 g I/kg body weight)
Number of subjects: 12
Study 2568805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 766157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone
Number of subjects: 45
Study 766157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31387377 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-SAVER intervention
Number of subjects: 66
Study 31387377 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study 31319426 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body compression garments
Number of subjects: 23
Study 31319426 — intervention group
Group type: COMPARATOR
Intervention: Control (no upper body compression garments)
Number of subjects: 23
Study 29569351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (3 times a week for 4 weeks)
Number of subjects: 111
Study 29569351 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 111
Study 29569351 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest)
Number of subjects: 111
Study 28644212 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsened AVC group
Number of subjects: 2964
Study 28644212 — intervention group
Group type: COMPARATOR
Intervention: Stable AVC group
Number of subjects: 2964
Study 26139208 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalon HSV-2 ELISA
Number of subjects: 837
Study 26139208 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of positive HSV-2 results
Number of subjects: 837
Study 26139208 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported virginity
Number of subjects: 837
Study 24176188 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable PSV
Number of subjects: 0
Study 24176188 — intervention group
Group type: COMPARATOR
Intervention: Non-variable PSV
Number of subjects: 0
Study 21393644 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy combined with standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Number of subjects: 30
Study 21393644 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Number of subjects: 30
Study 18312757 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290
Study 18312757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study 16649856 — intervention group
Group type: EXPERIMENTAL
Intervention: High power priming
Number of subjects: 6
Study 16649856 — intervention group
Group type: COMPARATOR
Intervention: Low power priming
Number of subjects: 6
Study 12846598 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) - passive maxillary plates during the first year of life
Number of subjects: 0
Study 12846598 — intervention group
Group type: COMPARATOR
Intervention: No intervention (IO-) - did not wear passive maxillary plates
Number of subjects: 0
Study 10803671 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/mL
Number of subjects: 132
Study 10803671 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg I/mL
Number of subjects: 132
Study 9032862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife treatment
Number of subjects: 36
Study 1909637 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg b.i.d.
Number of subjects: 18
Study 1909637 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg b.i.d. plus 4 g cholestyramine o.d.
Number of subjects: 18
Study 6614958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream applied daily to vitiliginous lesions under occlusive dressings
Number of subjects: 28
Study 6614958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream
Number of subjects: 28
Study 31774833 — intervention group
Group type: EXPERIMENTAL
Intervention: Topper Training
Number of subjects: 132
Study 31774833 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 132
Study 29026936 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded full-thickness blepharotomy (G1)
Number of subjects: 27
Study 29026936 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival Müller muscle recession and graded disinsertion of the levator palpebrae superioris muscle (G2)
Number of subjects: 27
Study 29026936 — intervention group
Group type: COMPARATOR
Intervention: Both groups (G1 and G2)
Number of subjects: 27
Study 26416521 — intervention group
Group type: EXPERIMENTAL
Intervention: long/GH
Number of subjects: 287
Study 26416521 — intervention group
Group type: EXPERIMENTAL
Intervention: short/GH
Number of subjects: 287
Study 24427348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 24427348 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 22209479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-hepatic fat
Number of subjects: 650
Study 22209479 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thoracic fat
Number of subjects: 650
Study 22209479 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial fat
Number of subjects: 650
Study 21108491 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver ring splint (SRS)
Number of subjects: 50
Study 21108491 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated thermoplastic splint (PTS)
Number of subjects: 50
Study 17609842 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFT)
Number of subjects: 115
Study 17609842 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal therapy (HT)
Number of subjects: 115
Study 17609842 — intervention group
Group type: COMPARATOR
Intervention: Sham horizontal therapy (Control)
Number of subjects: 115
Study 16271479 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 62
Study 16271479 — intervention group
Group type: EXPERIMENTAL
Intervention: Late open lung concept (LOL)
Number of subjects: 62
Study 16271479 — intervention group
Group type: EXPERIMENTAL
Intervention: Early open lung concept (EOL)
Number of subjects: 62
Study 12392122 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention group
Number of subjects: 0
Study 12392122 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence intervention group
Number of subjects: 0
Study 12392122 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus evidence intervention group
Number of subjects: 0
Study 12392122 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither intervention)
Number of subjects: 0
Study 9894691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic transformation in perspective of pairs of coplanar ellipses
Number of subjects: 0
Study 9894691 — intervention group
Group type: COMPARATOR
Intervention: Static upright view reproduction task
Number of subjects: 0
Study 7567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 9 mg/kg once daily (max 400 mg)
Number of subjects: 154
Study 7567311 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg/day in three divided doses (max 1 g/day)
Number of subjects: 154
Study 7567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 154
Study 7567311 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 154
Study 2095647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin preparation (Pentaglobin) administered intravenously
Number of subjects: 35
Study 7272608 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mourning treatment (facing cues concerning bereavement)
Number of subjects: 12
Study 7272608 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (avoiding cues concerning bereavement)
Number of subjects: 12
Study 31246103 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients
Number of subjects: 0
Study 31246103 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients with higher internalized stigma
Number of subjects: 0
Study 31246103 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients who avoided disclosure
Number of subjects: 0
Study 31246103 — intervention group
Group type: EXPERIMENTAL
Intervention: Married and older psychiatric patients
Number of subjects: 0
Study 31246103 — intervention group
Group type: COMPARATOR
Intervention: Medical patient controls
Number of subjects: 0
Study 30026002 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 295
Study 30026002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 26471889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0·015% gel
Number of subjects: 450
Study 26471889 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 450
Study 24501015 — intervention group
Group type: EXPERIMENTAL
Intervention: telehealth problem-solving therapy (tele-PST via Skype video call)
Number of subjects: 158
Study 24501015 — intervention group
Group type: EXPERIMENTAL
Intervention: in-person problem-solving therapy (PST)
Number of subjects: 158
Study 22819575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lignocaine (20 ml of 0.5% lignocaine)
Number of subjects: 196
Study 22819575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of isotonic saline)
Number of subjects: 196
Study 20045576 — intervention group
Group type: EXPERIMENTAL
Intervention: IV prochlorperazine with 12.5 mg diphenhydramine
Number of subjects: 68
Study 20045576 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 68
Study 20045576 — intervention group
Group type: EXPERIMENTAL
Intervention: IV prochlorperazine with diphenhydramine
Number of subjects: 68
Study 20045576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study 17336795 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress manipulation (anticipation of a public speaking task)
Number of subjects: 86
Study 17336795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 86
Study 15966756 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A induction (rifampicin)
Number of subjects: 13
Study 15966756 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A inhibition (troleandomycin)
Number of subjects: 13
Study 15966756 — intervention group
Group type: COMPARATOR
Intervention: Control (no CYP3A induction or inhibition)
Number of subjects: 13
Study 12464140 — intervention group
Group type: EXPERIMENTAL
Intervention: G. biloba extract (Gibidyl Forte(R))
Number of subjects: 16
Study 12464140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9493514 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a)
Number of subjects: 26
Study 7657737 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex depot (single injection)
Number of subjects: 142
Study 7657737 — intervention group
Group type: COMPARATOR
Intervention: Suprefact (multiple daily injections)
Number of subjects: 142
Study 2501372 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 11
Study 2501372 — intervention group
Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT)
Number of subjects: 11
Study 21345 — intervention group
Group type: EXPERIMENTAL
Intervention: etilefrin (Effortil Depot Perlongets)
Number of subjects: 24
Study 21345 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30378756 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback of the neck using mirrors (experimental group)
Number of subjects: 42
Study 30378756 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback (control group)
Number of subjects: 42
Study 28600818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks (q12 wk) maintenance (n=76)
Number of subjects: 378
Study 28600818 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab every 12-24 weeks (q12-24 wk) maintenance (n=302)
Number of subjects: 378
Study 28600818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks (q12 wk) maintenance
Number of subjects: 378
Study 28600818 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab every 12-24 weeks (q12-24 wk) maintenance
Number of subjects: 378
Study 25162967 — intervention group
Group type: COMPARATOR
Intervention: Low-dose metformin (250 mg/day)
Number of subjects: 120
Study 25162967 — intervention group
Group type: COMPARATOR
Intervention: Middle-dose metformin (500 mg/day)
Number of subjects: 120
Study 25162967 — intervention group
Group type: COMPARATOR
Intervention: High-dose metformin (1500 mg/day)
Number of subjects: 120
Study 25162967 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated with metformin)
Number of subjects: 120
Study 23486306 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Su‐Per treatment
Number of subjects: 40
Study 23486306 — intervention group
Group type: COMPARATOR
Intervention: Su‐Per treatment without higher stimulus at interspinous line
Number of subjects: 40
Study 21112173 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 926
Study 21112173 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD intervention
Number of subjects: 926
Study 21112173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 926
Study 19513760 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture (3 sessions)
Number of subjects: 66
Study 19513760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole (3x1000 mg)
Number of subjects: 66
Study 19513760 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 66
Study 16847010 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual thrombus in a patent epicardial artery
Number of subjects: 2684
Study 16847010 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 2684
Study 16847010 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2684
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Jump (SJ)
Number of subjects: 93
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ)
Number of subjects: 93
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: All jumping tests
Number of subjects: 93
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal Component Analysis of jumping tests
Number of subjects: 93
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: CMJ test
Number of subjects: 93
Study 15320660 — intervention group
Group type: EXPERIMENTAL
Intervention: Other jumping tests
Number of subjects: 93
Study 11752508 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (Cs) treatment
Number of subjects: 410
Study 11752508 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids (Cs) treatment
Number of subjects: 410
Study 10876967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral natural alpha‐Interferon (OROFERONE‐IFI) at 150U tid for 8 weeks
Number of subjects: 12
Study 10876967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8880052 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (12 mg, 30 mg, 60 mg)
Number of subjects: 0
Study 8880052 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (8 mg, 20 mg, 40 mg)
Number of subjects: 0
Study 2068049 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetyl carnitine (1.5 g, intravenously)
Number of subjects: 20
Study 2068049 — intervention group
Group type: COMPARATOR
Intervention: Sodium acetate (placebo)
Number of subjects: 20
Study 6350033 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 200 mg b.i.d. for 6 months
Number of subjects: 259
Study 6350033 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. for 6 months
Number of subjects: 259
Study 6350033 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 259
Study 6350033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 31302601 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMPT training package (Second edition)
Number of subjects: 87204
Study 31149001 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA airway cuff pressures adjusted to 30 to 32cm of H2O
Number of subjects: 80
Study 31149001 — intervention group
Group type: COMPARATOR
Intervention: Only monitoring of LMA cuff pressures
Number of subjects: 80
Study 30219052 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus ADCR
Number of subjects: 45
Study 26431466 — intervention group
Group type: EXPERIMENTAL
Intervention: IDflu9μg
Number of subjects: 86
Study 26431466 — intervention group
Group type: EXPERIMENTAL
Intervention: IDflu15μg
Number of subjects: 86
Study 26431466 — intervention group
Group type: COMPARATOR
Intervention: Agrippal
Number of subjects: 86
Study 24474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg days 1 and 15, rifampicin 600 mg days 8-14
Number of subjects: 0
Study 24474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg day 1, erlotinib 450 mg day 15, rifampicin 600 mg days 8-18
Number of subjects: 0
Study 24474302 — intervention group
Group type: COMPARATOR
Intervention: Control group (erlotinib 150 mg days 1 and 15)
Number of subjects: 0
Study 21946707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 99
Study 21946707 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 99
Study 21946707 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (overall)
Number of subjects: 99
Study 19305994 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI showing treatable pathology
Number of subjects: 274
Study 19305994 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy in group 1 patients
Number of subjects: 274
Study 19305994 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy in group 2 patients
Number of subjects: 274
Study 17242088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 17242088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 17242088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 17242088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 17242088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.4 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 17242088 — intervention group
Group type: COMPARATOR
Intervention: Control (no remifentanil)
Number of subjects: 72
Study 15919304 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leukocyte filtration
Number of subjects: 300
Study 12356782 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus 0.08 g/kg body weight of Z‐trim
Number of subjects: 24
Study 12356782 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus 0.17 g/kg body weight of Z‐trim
Number of subjects: 24
Study 12356782 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus 0.33 g/kg body weight of Z‐trim
Number of subjects: 24
Study 12356782 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (1 g/kg body weight)
Number of subjects: 24
Study 12356782 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus fiber (any level)
Number of subjects: 24
Study 9683311 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and omeprazole
Number of subjects: 3411
Study 9683311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with vitamin C, vitamin E, and selenium
Number of subjects: 3411
Study 9683311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with steam‐distilled garlic oil and Kyolic aged garlic extract
Number of subjects: 3411
Study 9683311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3411
Study 8086015 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty
Number of subjects: 44
Study 8086015 — intervention group
Group type: COMPARATOR
Intervention: Open acromioplasty
Number of subjects: 44
Study 8086015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 2676027 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response (educational information and practice before and after surgery)
Number of subjects: 27
Study 2676027 — intervention group
Group type: COMPARATOR
Intervention: Control group (only educational information)
Number of subjects: 27
Study 30851097 — intervention group
Group type: EXPERIMENTAL
Intervention: EOCS
Number of subjects: 318
Study 30851097 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 318
Study 28158703 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC) for 20 minutes
Number of subjects: 75
Study 28158703 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 75
Study 28158703 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 75
Study 25927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of parenteral nutrition (PN) beyond PICU-day 7 when enteral nutrition (EN) fails
Number of subjects: 1440
Study 25927936 — intervention group
Group type: COMPARATOR
Intervention: Early initiation of parenteral nutrition (PN) within the first days to reach caloric target (control group)
Number of subjects: 1440
Study 24432675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruji Recipe (RR) therapy
Number of subjects: 102